LMLaila-Yasmin Mani

Laila-Yasmin Mani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laila-Yasmin Mani has a total of 422 co-authors. Here are the top co-authors by number of shared publications:

  • Bruno Vogt

    Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

    6 shared publications
  • Bruno Vogt

    Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern

    4 shared publications
  • Giovambattista Capasso

    Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy

    3 shared publications
  • Jolanta Malyszko

    Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland

    3 shared publications
  • Peter Vermathen

    Magnetic Resonance Methodology, Institute of Diagnostic and Interventional Neuroradiology University of Bern Bern Switzerland

    3 shared publications
  • Sophie Liabeuf

    Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France

    3 shared publications

Latest Publications

  • Open Access

    Genome-wide studies define genetic mechanisms of IgA vasculitis

    by Lili Liu, Li Zhu, Sara Monteiro-Martins, Aaron Griffin, Lukas J. Vlahos, Masashi Fujita, Alexandria D. Taylor, Cecilia Berrouet, Francesca Zanoni, Maddalena Marasa, et al.

    IgA vasculitis is a pediatric disease with skin and systemic manifestations. Here, we conduct genome, transcriptome, and proteome-wide association studies in 2170 IgA vasculitis cases and 5928 controls, generate IgA vasculitis-specific maps of gene expression and splicing from blood of 255 pediatric cases, and reconstruct myeloid-specific regulatory networks to define disease master regulators modulated by the identified genes. We observe significant association at the HLA-DRB1 locus (OR = 1.55, P = 1.1 × 10−25) and fine-map specific amino-acid risk substitutions in DRβ1. We find two novel non-HLA associated loci: FCAR (OR = 1.51, P = 1.0 × 10−20), encoding a myeloid IgA receptor FcαR, and INPP5D (OR = 1.34, P = 2.2 × 10−09), encoding an inhibitor of FcαR signalling. The FCAR risk locus co-localizes with a cis-eQTL that increases FCAR expression; the risk alleles disrupt a PRDM1 binding motif within a myeloid enhancer of FCAR. Another risk locus is associated with higher genetically predicted levels of plasma IL6R. The IL6R risk haplotype carries a missense variant contributing to accelerated cleavage of IL6R into a soluble form. Applying network-based approaches to blood single cell transcriptomes, we predict, independently replicate, and experimentally validate 21 IgA vasculitis master regulators co-modulated by FCAR, INPP5D and IL6R signalling in myeloid cells.


  • Open Access

    Impact of Disease Recurrence and Outcomes following Kidney Transplantation for GN

    by Matthieu Halfon, Patrick Taffé, Christian Bucher, Fadi Haidar, Uyen Huynh-Do, Laila-Yasmin Mani, Thomas Schachtner, Caroline Wehmeier, Jean-Pierre Venetz, Manuel Pascual, et al.

    Key Points: GN is one of the main causes of kidney transplantation. In patients transplanted for GN, the risk of recurrence is approximately 16%. Recurrence significantly worsens the prognostic, tripling and doubling the risk of graft loss and acute rejection, respectively. Despite having more often received immunosuppression before transplantation, patients with GN are not at increased risk of post-transplantation cancers. Background: Patients who receive transplants after kidney failure due to GN (GN-KTx) constitute a significant portion of recipients and may face unique challenges post-transplantation, related to the risk of GN recurrence and a higher global burden of immunosuppression. Methods: We analyzed patient and graft outcomes, including the risk of graft loss in relation to recurrence in GN-KTx, compared with patients transplanted for other causes, using data from the prospective nationwide Swiss Transplant Cohort Study. Results: Among 2631 included patients, 701 were GN-KTx, with IgA nephropathy being the most common GN subtype. GN-KTx recipients were younger and more likely to receive living donor organs. During a mean follow-up period of 5.3 years (interquartile range, 2.3–8.2), the 5-year cumulative incidence of graft loss was similar across groups, with GN-KTx at 6%. Notably, GN-KTx had a similar incidence of acute rejection as other groups. Recurrence occurred in 16% of GN-KTx within a mean time of 1.7 years (interquartile range, 0.28–2). Patients with recurrence faced a three-fold higher risk of graft loss. Furthermore, disease recurrence was associated with a two-fold higher risk of acute rejection compared with nonrecurrent GN-KTx. Interestingly, regarding cancer risks, GN-KTx patients had the lowest incidence of skin cancer and no higher risk of nonskin cancers, despite greater exposure to immunosuppression compared with other kidney transplant recipients. Conclusions: These real-life setting contemporary multicenter data highlight the importance of post-transplant monitoring for GN recurrence, given the strong association with poor graft outcomes and higher rejection rates. This is important in the context of current development of targeted therapies for GN in native kidneys that could be transposed to transplanted kidneys.


  • Open Access

    Treatment practices, characteristics and outcome of immunoglobulin A nephropathy – a Swiss single center experience

    by Danny Thieny Taing, Bruno Vogt, Laila-Yasmin Mani

    Introduction: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Geographic differences in disease course and treatment response are well recognized. The purpose of this analysis was to study clinical and histological characteristics, treatment practices and outcome of IgAN cases from a Swiss tertiary center. Methods: This retrospective cohort analysis identified 158 cases of adult biopsy-proven IgAN by chart review diagnosed between 1980 and 2016. Following detailed phenotyping, standard descriptive methods and univariate analysis were applied. Results: The majority of patients was male and of European ancestry. At diagnosis, mean estimated glomerular filtration rate (eGFR) was 55.7 ml/min/1.73 m 2 , mean proteinuria was 2.4 g/d and 69.9% of the patients were hypertensive. Clinical presentation varied according to age. Initial biopsies showed moderate to severe tubular atrophy and interstitial fibrosis (IFTA) in 29.1% and crescents in 36.7% of cases. Therapy included renin-angiotensin-aldosterone-inhibitors in 86.7% as well as immunosuppressive therapy in 46.8% including steroids and other immunosuppressive drugs (28.7%), mainly azathioprin. Outcome included 34.1% complete and 22.2% partial remissions, relapses in 32.0% of patients, while 43.0% of patients progressed to ESKD during follow-up (median 100.0 months). Recurrence rate after transplantation was 18.8%. Immunosuppressive therapy was more frequently used in patients with higher proteinuria level, higher hematuria grade, lower eGFR, more intense IgA and complement C3 staining and crescents. Predictors of progression were higher age, lower eGFR, higher proteinuria and blood pressure as well as crescents and higher extent of IFTA on the initial biopsy. Conclusions: This retrospective cohort analysis gives insight into characteristics and outcome of patients with IgAN from a Swiss tertiary center, treatment practices as well as predictors of outcome and therapy choices. A comparatively high use of immunosuppressive treatment including non-steroid-based regimens was found along with a high rate of progression to ESKD.

  • Open Access

    Characteristics and Outcome of Immunoglobulin A Nephropathy – a Swiss single center experience

    by Danny Thieny Taing, Bruno Vogt, Laila-Yasmin Mani

    Background: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Geographic differences in disease course and treatment response are well recognized. The purpose of this analysis was to study clinical and histological characteristics, treatment practices and outcome of IgAN cases from a Swiss tertiary center. Methods: This retrospective cohort analysis identified 158 cases of adult biopsy-proven IgAN by chart review diagnosed between 1980 and 2017. Following detailed phenotypisation, standard descriptive methods and univariate analysis corrected by the Bonferroni method were applied. Results: Patients were majorly male and of Caucasian descent. At diagnosis, mean estimated glomerular filtration rate (eGFR) was 55.4 ml/min/1.73 m 2 , mean proteinuria was 2.4 g/d, 69.9% of the patients were hypertensive. Clinical presentation varied according to age. Initial biopsies showed moderate to severe tubular atrophy and interstitial fibrosis (IFTA) in 29.1% and crescents in 36.7% of cases. Therapy included renin-angiotensin-aldosterone-inhibitors in 86.7%, immunosuppressive therapy in 46.8% including steroids and other immunosuppressive drugs (28.7%), mainly azathioprin. Outcome included 34.1% complete and 22.2% partial remissions, relapses in 32.0% of patients, while 43.0% of patients progressed to ESKD during follow-up (median 100.0 months). Recurrence rate after transplantation was 18.8%. Immunosuppressive therapy was more frequently used in patients with higher proteinuria level and crescents. Predictors of progression were lower eGFR, higher proteinuria and higher extent of IFTA on the initial biopsy. Conclusions: This retrospective cohort analysis gives insight into characteristics and outcome of patients with IgAN from a Swiss tertiary center, treatment practices as well as predictors of outcome and therapy choices. Key learning points: What was known: A wide range of clinical presentations exists for immunoglobulin A nephropathy (IgAN) pointing to IgAN as a disease spectrum rather than a single disease entity Additional important geographic differences regarding disease prevalence, disease course and response to therapies have been recognized Progression to end-stage kidney disease (ESKD) occurs in a substantial part of affected patients This study adds: In this cohort, a comparatively high proportion of patients was treated by immunosuppressive therapy including non-steroid treatment underlining the heterogeneous nature of treatment practices worldwide Predictors of the use of immunosuppressive therapy in this cohort have been identified Similarly to recent UK registry data, a high rate of progression to ESKD has been found including patients with low baseline proteinuria level Potential impact: These findings further underline the importance of achieving an improved characterization and pathogenetic understanding of IgAN disease subtypes through ongoing research efforts At the beginning of the current new therapeutic era for patients with IgAN, this goal has now become more relevant than ever


  • Open Access

    Chemotherapy-related cognitive impairment and kidney dysfunction

    by Mariadelina Simeoni, Michele M Mulholland, Biruh T Workeneh, Anna Capasso, Gaye Hafez, Sophie Liabeuf, Jolanta Malyszko, Laila-Yasmin Mani, Francesco Trevisani, Ananya De, et al.

    Cancer and kidney diseases (KD) intersect in many ways resulting in worse outcomes. Both conditions are correlated with cognitive impairment, which can be exacerbated in cancer patients by known effects of many antineoplastic drugs on cognition, leading to a phenomenon known as chemotherapy-related cognitive impairment (CRCI). This manifests as poor attention span, disturbed short-term memory, and general mental sluggishness. This literature review explores CRCI and investigates the potential impact of KD on this phenomenon. Additionally, we highlight the shared pathogenetic mechanisms (including neurotoxicity, neuroinflammation, oxidative stress, vascular disease, electrolyte, and acid-base imbalances), clinical presentation and imaging findings between cognitive impairment in KD and CRCI. The disruption of the blood–brain barrier might be a key mechanism for increased brain permeability to anticancer drugs in nephropathic patients with cancer. Based on existing knowledge, we found a potential for heightened neurotoxicity of antineoplastic drugs and a synergistic potentiation of cognitive impairment in cancer patients with KD. However, further translational research is urgently required to validate this hypothesis.


  • Open Access

    Cognitive impairment in chronic kidney disease: role of brain imaging, functional imaging, electroencephalography, cerebrospinal fluid biomarkers and sensors

    by Alexandre Andrade, Maie Bachmann, Mickaël Bobot, Annette Bruchfeld, Ivo Fridolin, Laila-Yasmin Mani, Hong Xu, CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target) collaborators

    Chronic kidney disease is associated with cognitive impairment although the underlying mechanisms are still not fully understood. Characterization and efficient monitoring of the cognitive impact of kidney disease and ensuing therapies are critical for the accurate clinical management of patients. A vast array of imaging modalities, biomarkers, and sensors have shown relevance for the assessment of cognitive impairment. Knowing the potential and limitations of these paraclinical techniques is a necessary condition to improve the understanding of this phenomenon and to design monitoring protocols and guidelines applicable to this clinical population. The goal of this review is to provide an overview of current imaging modalities and biomarker sources available to the community, for the benefit of the research and clinical community.


  • Open Access

    Editorial: Factors affecting graft survival after renal transplant: prevention of failure and follow-up strategies

    by Laila-Yasmin Mani

    Since its first introduction in 1951 1 , kidney transplantation has become the best therapeutic option for patients affected by end-stage kidney disease. Indeed, kidney transplant recipients experience a clear survival benefit when compared to their matched counterparts on the waiting list. 2 Thanks to the development of highly effective immunosuppressive regimens, the much-feared threat of acute organ rejection could be well mastered. Surprisingly, despite these major advancements, a trend for decreased graft survival has been recorded over recent decades. 3 Considered the final common pathway of all transplanted kidneys, the interstitial fibrosis and tubular atrophy (IFTA)-lesion of the kidney graft is thought to be multifactorial in origin secondary to immunological, cardiovascular, toxic and infectious causes. 4 In this Research Topic, 15 articles of various formats from different geographic regions in the world invite us to shed light on diverse aspects of long-term kidney graft function.Biopsy-proven causes for graft failure after a very long follow-up up to 26 years were examined by Betjes et al. in a prospective Dutch cohort of 737 kidney transplant recipients (Betjes et al.). The category of rejection accounted for the main part of death-censored graft survival while recipient's age, time after transplantation, and the presence of donor-specific antibodies before transplantation determined the relative contribution to overall graft loss and the type of rejection involved.The influence of age and sex on graft survival was analysed by Sancho and colleagues in a retrospective Spanish cohort of 1101 kidney transplant recipients (Sancho et al.). The lower graft survival of female patients under 60 years of age was attributed to a more frequent use of expanded criteria donors and a higher prevalence of pre-transplant human leukocyte antigen sensitization.Furthermore, the influence of donor race was examined in a retrospective clinicopathological analysis from Columbia University NY on roughly 1900 kidney transplant recipients. The authors confirmed a shorter allograft survival of kidney grafts from black donors and revealed a higher risk for the development of collapsing glomerulopathy in grafts from black donors (DiFranza).Infections as cause of late graft loss and complicated post-transplant course were the topic of several reports in this collection. Brune et al. found no impact of first year urinary tract infection (UTI) episodes with extended-spectrum beta-lactamase (ESBL) Escherichia coli and Klebsiella species on graft survival in 389 kidney transplant recipients within the Swiss Transplant Cohort while hospitalization and UTI recurrence rates were higher compared to patients affected by UTI with non-ESBL-producing strains (Brune et al.). In an Italian retrospective cohort of 939 kidney transplant recipients, MRI-confirmed acute graft pyelonephritis was associated with reduced death-censored graft survival influenced by donor age, multifocal presentation and abcedation as well as anti-thymocyte glogulin induction (Tarragoni et al. Finally, functional kidney graft ischemia has been evoked as cause for the development of IFTA. In our center, we have examined the hypothesis that grafts are less oxygenated during the sitting position due to kinking or bending of the iliacal vessels analogous to iliacal claudication described in professional cyclists. Using a multiparametric functional kidney MRI protocol including blood oxygen level-dependent (BOLD)-MRI, diffusion-MRI and arterial spin labeling-MRI during neutral and flexed hip position, the Bent Knee Study showed an acute impact of hip flexion on graft perfusion and oxygenation (Mani et al.).Immune-dependent factors play a well-known role for kidney graft survival with rejection episodes contributing to early and late graft loss. Therefore monitoring of immunosuppression has a major role in preventing rejection and avoiding infectious and toxic complications. Reineke et al. correlated Torque teno virus load in 106 kidney transplant recipients undergoing indication biopsies to histological findings and conclude that Torque teno virus load may reflect changes in immunosuppressive therapy even after the first year post-transplant (Reineke et al.). In a proof-of-principle study by Born et al. in

  • Open Access

    Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis

    by Matthieu Halfon, Patrick Taffé, Christian Bucher, Fadi Haidar, Uyen Huynh-Do, Laila-Yasmin Mani, Thomas Schachtner, Caroline Wehmeier, Jean-Pierre Venetz, Manuel Pascual, et al.


  • Open Access

    Non-invasive Real-time Detection of Potassium level Changes in Skeletal Muscles during Exercise by Magnetic Resonance Spectroscopy

    by Etienne Roesli, Hedvika Haindrich Primasová, Marc Thiede, Laila-Yasmin Mani, Lena V. Gast, Armin M. Nagel, Bruno Vogt, Peter Vermathen

    Introduction: Potassium is essential in cellular functions, with specific importance in muscle activity and cardiovascular health. It is the main intracellular cation in the human body with 70% located in muscle. Traditional methods to measure potassium levels are invasive and lack specificity for intracellular concentrations. Recently, non-invasive in vivo investigation of K+ ion homeostasis has become feasible by using K Magnetic Resonance Imaging (MRI) and MR spectroscopy (MRS) at ultrahigh magnetic fields. However, studies demonstrating the sensitivity of K MRI or MRS to detect potassium alterations in disease or upon intervention are sparse. This study utilizes K MRS to non-invasively track real-time intramuscular potassium changes during exercise, providing an assessment of potassium dynamics and explores the potential for technical artifacts in the measurements. Methods: Five healthy subjects (three males, two females) were recruited to perform standardized dynamic knee extensions inside a 7T MR scanner. Potassium levels were measured using a K MRS protocol that included periods of rest, moderate, and heavy exercise followed by recovery. Additionally, possible measurement artifacts due to muscle movement or changes in coil position relative to the thigh were evaluated using K MRS and H MRI monitoring in separate sessions. Results: The study revealed a consistent decrease in potassium levels during both moderate and heavy exercise, with an average decrease of 5-6%. These changes were rapidly detectable and were reversed upon cessation of exercise, indicating effective in vivo monitoring capability. Possible experimental artifacts were investigated, and the results suggested not to be responsible for the detected potassium changes during exercise. The results of the non-localized K MRS measurements during exercise correlated well with expected physiological changes based on previous literature. Discussion: The application of K MRS provides a valuable non-invasive tool for studying potassium dynamics in human skeletal muscle. This technique could enhance our understanding of muscle physiology and metabolic disorders. The ability to measure these changes in real time and non-invasively highlights the potential for clinical applications, including monitoring of diseases affecting muscle and cellular metabolism.


  • Open Access

    Drugs with a negative impact on cognitive functions (part 3): antibacterial agents in patients with chronic kidney disease

    by Sophie Liabeuf, Gaye Hafez, Vesna Pešić, Goce Spasovski, Mickaël Bobot, Romaldas Mačiulaitis, Inga Arune Bumblyte, Ana Carina Ferreira, Ana Farinha, Jolanta Malyszko, et al.

    The relationship between chronic kidney disease (CKD) and cognitive function has received increased attention in recent years. Antibacterial agents (ABs) represent a critical component of therapy regimens in patients with CKD due to increased susceptibility to infections. Following our reviewing work on the neurocognitive impact of long-term medications in patients with CKD, we propose to focus on AB-induced direct and indirect consequences on cognitive function. Patients with CKD are predisposed to adverse drug reactions (ADRs) due to altered drug pharmacokinetics, glomerular filtration decline, and the potential disruption of the blood–brain barrier. ABs have been identified as a major cause of ADRs in vulnerable patient populations. This review examines the direct neurotoxic effects of AB classes (e.g. beta-lactams, fluoroquinolones, aminoglycosides, and metronidazole) on the central nervous system (CNS) in patients with CKD. We will mainly focus on the acute effects on the CNS associated with AB since they are the most extensively studied effects in CKD patients. Moreover, the review describes the modulation of the gut microbiota by ABs, potentially influencing CNS symptoms. The intricate brain–gut–kidney axis emerges as a pivotal focus, revealing the interplay between microbiota alterations induced by ABs and CNS manifestations in patients with CKD. The prevalence of antibiotic-associated encephalopathy in patients with CKD undergoing intravenous AB therapy supports the use of therapeutic drug monitoring for ABs to reduce the number and seriousness of ADRs in this patient population. In conclusion, elucidating AB-induced cognitive effects in patients with CKD demands a comprehensive understanding and tailored therapeutic strategies that account for altered pharmacokinetics and the brain–gut–kidney axis.